In the 2022 installment of THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT, there are eight companies with revenue between $400 million and $999 million. Only one of those companies, Globus Medical, grew more than 20% compared to 2019 without the benefit of significant acquisitions. Globus’s compelling combination of spinal hardware and robotics has drawn new surgeons and competitive sales reps into the fold.
In this month’s chart, we look at six years of orthopedic sales for the eight companies in the $400 million to $999 million revenue range. Globus’ rapid rise through the revenue ranks leaves it on the cusp of becoming a $1 billion orthopedic player with a portfolio aimed at broadening its reach into segments beyond spine.
Globus Medical’s recent stretch of double-digit growth is virtually all organic and leaves the company with a war chest to deploy for an acquisition. The company is unlikely to purchase anything in the spine segment but could make a splash in fast-growing categories like shoulder or foot-and-ankle.
Whatever the choice, the company will embark on the next phase of its evolution under the guidance of new CEO Dan Scavilla, who has been with Globus since 2015. Mr. Scavilla held several vital roles like CFO, COO and President of Trauma before his appointment to CEO. We expect his tenure will broaden Globus’ reach across other product segments as it competes directly with the largest orthopedic players.
In the 2022 installment of THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT, there are eight companies with revenue between $400 million and $999 million. Only one of those companies, Globus Medical, grew more than 20% compared to 2019 without the benefit of significant acquisitions. Globus’s compelling combination of spinal hardware and robotics has drawn...
In the 2022 installment of THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT, there are eight companies with revenue between $400 million and $999 million. Only one of those companies, Globus Medical, grew more than 20% compared to 2019 without the benefit of significant acquisitions. Globus’s compelling combination of spinal hardware and robotics has drawn new surgeons and competitive sales reps into the fold.
In this month’s chart, we look at six years of orthopedic sales for the eight companies in the $400 million to $999 million revenue range. Globus’ rapid rise through the revenue ranks leaves it on the cusp of becoming a $1 billion orthopedic player with a portfolio aimed at broadening its reach into segments beyond spine.
Globus Medical’s recent stretch of double-digit growth is virtually all organic and leaves the company with a war chest to deploy for an acquisition. The company is unlikely to purchase anything in the spine segment but could make a splash in fast-growing categories like shoulder or foot-and-ankle.
Whatever the choice, the company will embark on the next phase of its evolution under the guidance of new CEO Dan Scavilla, who has been with Globus since 2015. Mr. Scavilla held several vital roles like CFO, COO and President of Trauma before his appointment to CEO. We expect his tenure will broaden Globus’ reach across other product segments as it competes directly with the largest orthopedic players.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE
ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
Copy to clipboard 
